Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease ...

Nutritional deficiencies are common after Roux-en-Y gastric bypass (RYGB) surgery. However, severe zinc deficiency is a ...

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight upcoming milestones for its messenger RNA (mRNA) rare disease pipeline, with C ...

Arcturus fait progresser ARCT-032 vers une étude de phase 2b pour la mucoviscidose, ciblant les patients ne répondant pas aux modulateurs. La clarté réglementaire pour ARCT-810, un actif potentiel de ...

Background and Aim: Hepatic encephalopathy continues to be a major clinical problem and the current decade has not witnessed major therapeutic breakthroughs in this area. L-ornithine-L-aspartate (LOLA ...

First in vivo gene insertion clinical trial dosing infants reports complete clinical response in the first participant at the lowest dose level (1.3 x 10 13 GC/kg) of ECUR-506 from three months post ...

Cirrhosis is a chronic disorder of the liver. People with this condition commonly develop hepatic encephalopathy, a complication that results in poor brain functioning. Some people with cirrhosis ...

SAN DIEGO, June 30, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of ...

SAN DIEGO--(BUSINESS WIRE)--$ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA ...

La cirrhose est une maladie chronique du foie. Les personnes atteintes de cette maladie développent généralement une encéphalopathie hépatique, complication qui entraîne un mauvais fonctionnement du ...